in clinical trials is vital – delays are costly to sponsors and to patients.
If patients fail to sign on in adequate numbers ...
the assessment of the therapy will not be made
no matter how well the study is designed from the point of view of regulators and scientists.
Indeed, the urgency of our situation requires that the evaluation system
becomes as efficient as it can be.
in efficiency and faster accrual
prepare continuously by reviewing reputable
materials on drug development
and assessment, and by seeking guidance
from our scientific advisors.
Importantly, to minimize bias, our policy is to accept no funding from
commercial entities that market drugs or health supplements.
We are committed to:
- Sharing patient's perspectives on clinical
trial design with the FDA, drug sponsors,
the NCI, independent scientists, and community physicians.
- Making informed and practical
suggestions when consulting on clinical trial design.
Note that we will not accept gifts or fees for this service,
and that we will honor
- Vigorously representing patient interests in
matters of concern.
- Identifying opportunities and obstacles to
the progress of clinical research.
We believe that
the following goals must not be considered mutually
Applying the best possible
evidence-based standards to ensure that patients
have reliable information about the risks and benefits of marketed
and increasing incentives for companies to develop new
therapies to meet our needs.
Providing cancer patients with
every reasonable chance to improve their
quality of life
Patient Perspectives: the details
Guidance on clinical trial design for drug sponsors and the
FDA Patient perspectives
Itemizing opportunities and challenges in FDA evaluations of
new drugs Patient perspectives
Would a clinical trial
be appropriate for me? Questions for your doctor
A printable brochure prepared by
Patients Against Lymphoma PDF | PDF-Help
Harmonizing Research and Treatment Goals - Patients
Against Lymphoma Presentation
Cancer Vaccine Conference in Boston - April 2003
Overcoming obstacles to participation in clinical trials Patient
A checklist that will help all parties to overcome known